Search results
There's another COVID variant you should know about: KP.3 now makes up 25% of COVID cases
USA Today· 5 days agoThe Centers for Disease Control and Prevention data shows that a new COVID variant, the KP.3...
FDA Roundup: June 7, 2024
The Pilot News· 6 days agoToday, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID ...
FDA Roundup: June 7, 2024
Morning Times· 6 days agoToday, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID ...
MFP Impact, Media and Awards 2023
Mississippi Free Press· 22 minutes agoThe Meridian Star published an opinion column about transparency in Mississippi’s state government that centered on the state Ethics Commission ‘s ruling that the state legislature is not a ...
Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
The Sacramento Bee· 4 days agomRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older, including an enhanced influenza vaccine in adults 65 years and...
Morning update: What you need to know in Maine today
Bangor Daily News· 3 days agoVoters will choose party candidates for three federal races and the Maine Legislature, plus school budgets and various local questions. The...
Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal
Zacks via Yahoo Finance· 2 days agoData from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination...
Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
Digital Journal· 4 days agoFood & Drug Administration...classification, development and regulatory submission strategy for a point-of-care in vitro diagnostic device that aids in the detection of post COVID< ...
Going Down?
Reason.com via Yahoo Finance· 1 day agoAmericans are understandably eager to see both inflation and interest rates fall toward the historically low levels that were enjoyed before the COVID-19
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with...
Morningstar· 1 day agoPfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin ...
